Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejectio   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme